Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- HRP Rabbit monoclonal [Y78] to MEK2
- Suitable for: WB
- Knockout validated
- Reacts with: Human
- Conjugation: HRP
Product nameHRP Anti-MEK2 antibody [Y78]
See all MEK2 primary antibodies
DescriptionHRP Rabbit monoclonal [Y78] to MEK2
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Human
Predicted to work with: Mouse
Synthetic peptide. within Human MEK2 aa 1 to the C-terminus (N terminal). The exact sequence is proprietary.
Database link: P36507
- WB: Jurkat whole cell lysate.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. Store In the Dark.
Storage bufferpH: 7.40
Preservative: 0.1% 10% Proclin 300 Solution
Constituents: PBS, 30% Glycerol, 1% BSA
Concentration information loading...
PurityProtein A purified
- Alexa Fluor® 647 Anti-MEK2 antibody [Y78] (ab200519)
- Alexa Fluor® 488 Anti-MEK2 antibody [Y78] (ab200606)
- PE Anti-MEK2 antibody [Y78] (ab213661)
- Alexa Fluor® 555 Anti-MEK2 antibody [Y78] (ab214633)
- Alexa Fluor® 594 Anti-MEK2 antibody [Y78] (ab214845)
- Anti-MEK2 antibody [Y78] - BSA and Azide free (ab233731)
- Anti-MEK2 antibody [Y78] (ab32517)
Our Abpromise guarantee covers the use of ab200607 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/7500. Detects a band of approximately 45 kDa (predicted molecular weight: 44 kDa).|
FunctionCatalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates the ERK1 and ERK2 MAP kinases.
Involvement in diseaseDefects in MAP2K2 are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant.
Sequence similaritiesBelongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase subfamily.
Contains 1 protein kinase domain.
modificationsMAPKK is itself dependent on Ser/Thr phosphorylation for activity catalyzed by MAP kinase kinase kinases (RAF or MEKK1).
Acetylation of Ser-222 and Ser-226 by Yersinia yopJ prevents phosphorylation and activation, thus blocking the MAPK signaling pathway.
- Information by UniProt
- Cardiofaciocutaneous syndrome antibody
- CFC syndrome antibody
- CFC4 antibody
All lanes : HRP Anti-MEK2 antibody [Y78] (ab200607) at 1/7500 dilution
Lane 1 : Wild-type HAP1 whole cell lysate
Lane 2 : MAP2K2 (MEK2) knockout HAP1 whole cell lysate
Lysates/proteins at 20 µg per lane.
Predicted band size: 44 kDa
Observed band size: 44 kDa
Exposure time: 30 seconds
ab200607 was shown to specifically react with MEK2 in wild-type HAP1 cells as signal was lost in MAP2K2 (MEK2) knockout cells. Wild-type and MAP2K2 (MEK2) knockout samples were subjected to SDS-PAGE. Ab200607 and ab184095 (Mouse monoclonal [mAbcam 9484] to GAPDH - Loading Control (Alexa Fluor® 680) loading control) were incubated overnight at 4°C at 1/7500 dilution and 1/1000 dilution respectively. The loading control was imaged using the Licor Odyssey CLx prior to blots being developed with ECL technique.
HRP Anti-MEK2 antibody [Y78] (ab200607) at 1/7500 dilution + Jurkat (Human T cell lymphoblast-like cell line) Whole Cell Lysate at 10 µg
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 44 kDa
Observed band size: 45 kDa why is the actual band size different from the predicted?
Additional bands at: 100 kDa. We are unsure as to the identity of these extra bands.
Exposure time: 10 seconds
This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 2% Bovine Serum Albumin before being incubated with ab200607 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.
ab200607 has not yet been referenced specifically in any publications.